Media coverage about Inovio Pharmaceuticals (NASDAQ:INO) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Inovio Pharmaceuticals earned a news impact score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.1927107405946 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s analysis:
- INO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study (globenewswire.com)
- Inovio Pharma Reports Promising Phase 1b Clinical Trial Data Of INO-5150 (rttnews.com)
- Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer (finance.yahoo.com)
- Inovio Pharmaceuticals, Inc. (INO) Earns Buy Rating from Analysts at Citigroup Inc. (americanbankingnews.com)
- Inovio Pharmaceuticals, Inc. (INO) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
Inovio Pharmaceuticals (INO) traded up 0.50% during midday trading on Tuesday, hitting $6.06. The stock had a trading volume of 781,831 shares. The company’s 50 day moving average price is $5.68 and its 200-day moving average price is $6.70. The stock’s market cap is $546.78 million. Inovio Pharmaceuticals has a 52-week low of $5.28 and a 52-week high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million during the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. Inovio Pharmaceuticals’s revenue was up 229.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) EPS. Analysts forecast that Inovio Pharmaceuticals will post ($0.92) EPS for the current fiscal year.
INO has been the topic of several recent research reports. Zacks Investment Research raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 15th. Aegis reaffirmed a “buy” rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 17th. Maxim Group upped their price target on Inovio Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Thursday, May 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Inovio Pharmaceuticals in a research note on Sunday, May 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $19.80.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.